Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment

Mahmoud S. Assaf, Eric Laille, Liangang Liu, Edward O'Mara, Anfan Wu, Maria Palmisano, Thomas C. Marbury, Richard A Preston

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Apremilast (CC-10004), a PDE4 enzyme inhibitor, is under clinical development for the treatment of inflammatory immune-mediated disorders. Since apremilast is extensively metabolised via multiple routes, impact of hepatic impairment on the pharmacokinetics (PK) of apremilast and M12 metabolite was evaluated. Thirty-two subjects were enrolled in a two-centre, open-label, and single-dose study. Subjects with moderate hepatic impairment and their healthy matches received a single 30-mg dose and subjects with severe hepatic impairment and their healthy matches received a single 20-mg dose of apremilast. Plasma concentrations of apremilast and M12 were measured, PK parameters calculated, and statistically compared. During the study, single doses of apremilast were well tolerated, with no clinically meaningful safety findings observed. PK parameters were comparable between hepatic impaired and healthy subjects, and there was no evidence to suggest that the PK of apremilast is affected by moderate and severe hepatic impairment. Therefore, no dose adjustment is required.

Original languageEnglish
Pages (from-to)100-114
Number of pages15
JournalInternational Journal of Medical Engineering and Informatics
Volume6
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pharmacokinetics
Safety
Liver
Metabolites
Labels
Enzymes
Phosphodiesterase 4 Inhibitors
Plasmas
apremilast
Immune System Diseases
Enzyme Inhibitors
Healthy Volunteers

Keywords

  • Apremilast
  • Hepatic impairment
  • Hepatic metabolism
  • PDE4
  • Pharmacokinetics
  • Phosphodiesterase 4
  • PK

ASJC Scopus subject areas

  • Biomedical Engineering
  • Health Informatics
  • Medicine (miscellaneous)
  • Biomaterials

Cite this

Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment. / Assaf, Mahmoud S.; Laille, Eric; Liu, Liangang; O'Mara, Edward; Wu, Anfan; Palmisano, Maria; Marbury, Thomas C.; Preston, Richard A.

In: International Journal of Medical Engineering and Informatics, Vol. 6, No. 2, 01.01.2014, p. 100-114.

Research output: Contribution to journalArticle

Assaf, Mahmoud S. ; Laille, Eric ; Liu, Liangang ; O'Mara, Edward ; Wu, Anfan ; Palmisano, Maria ; Marbury, Thomas C. ; Preston, Richard A. / Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment. In: International Journal of Medical Engineering and Informatics. 2014 ; Vol. 6, No. 2. pp. 100-114.
@article{0ca16d8b5e214e7c89e7b587146c183e,
title = "Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment",
abstract = "Apremilast (CC-10004), a PDE4 enzyme inhibitor, is under clinical development for the treatment of inflammatory immune-mediated disorders. Since apremilast is extensively metabolised via multiple routes, impact of hepatic impairment on the pharmacokinetics (PK) of apremilast and M12 metabolite was evaluated. Thirty-two subjects were enrolled in a two-centre, open-label, and single-dose study. Subjects with moderate hepatic impairment and their healthy matches received a single 30-mg dose and subjects with severe hepatic impairment and their healthy matches received a single 20-mg dose of apremilast. Plasma concentrations of apremilast and M12 were measured, PK parameters calculated, and statistically compared. During the study, single doses of apremilast were well tolerated, with no clinically meaningful safety findings observed. PK parameters were comparable between hepatic impaired and healthy subjects, and there was no evidence to suggest that the PK of apremilast is affected by moderate and severe hepatic impairment. Therefore, no dose adjustment is required.",
keywords = "Apremilast, Hepatic impairment, Hepatic metabolism, PDE4, Pharmacokinetics, Phosphodiesterase 4, PK",
author = "Assaf, {Mahmoud S.} and Eric Laille and Liangang Liu and Edward O'Mara and Anfan Wu and Maria Palmisano and Marbury, {Thomas C.} and Preston, {Richard A}",
year = "2014",
month = "1",
day = "1",
doi = "10.1504/IJMEI.2014.060246",
language = "English",
volume = "6",
pages = "100--114",
journal = "International Journal of Medical Engineering and Informatics",
issn = "1755-0653",
publisher = "Inderscience Enterprises Ltd",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment

AU - Assaf, Mahmoud S.

AU - Laille, Eric

AU - Liu, Liangang

AU - O'Mara, Edward

AU - Wu, Anfan

AU - Palmisano, Maria

AU - Marbury, Thomas C.

AU - Preston, Richard A

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Apremilast (CC-10004), a PDE4 enzyme inhibitor, is under clinical development for the treatment of inflammatory immune-mediated disorders. Since apremilast is extensively metabolised via multiple routes, impact of hepatic impairment on the pharmacokinetics (PK) of apremilast and M12 metabolite was evaluated. Thirty-two subjects were enrolled in a two-centre, open-label, and single-dose study. Subjects with moderate hepatic impairment and their healthy matches received a single 30-mg dose and subjects with severe hepatic impairment and their healthy matches received a single 20-mg dose of apremilast. Plasma concentrations of apremilast and M12 were measured, PK parameters calculated, and statistically compared. During the study, single doses of apremilast were well tolerated, with no clinically meaningful safety findings observed. PK parameters were comparable between hepatic impaired and healthy subjects, and there was no evidence to suggest that the PK of apremilast is affected by moderate and severe hepatic impairment. Therefore, no dose adjustment is required.

AB - Apremilast (CC-10004), a PDE4 enzyme inhibitor, is under clinical development for the treatment of inflammatory immune-mediated disorders. Since apremilast is extensively metabolised via multiple routes, impact of hepatic impairment on the pharmacokinetics (PK) of apremilast and M12 metabolite was evaluated. Thirty-two subjects were enrolled in a two-centre, open-label, and single-dose study. Subjects with moderate hepatic impairment and their healthy matches received a single 30-mg dose and subjects with severe hepatic impairment and their healthy matches received a single 20-mg dose of apremilast. Plasma concentrations of apremilast and M12 were measured, PK parameters calculated, and statistically compared. During the study, single doses of apremilast were well tolerated, with no clinically meaningful safety findings observed. PK parameters were comparable between hepatic impaired and healthy subjects, and there was no evidence to suggest that the PK of apremilast is affected by moderate and severe hepatic impairment. Therefore, no dose adjustment is required.

KW - Apremilast

KW - Hepatic impairment

KW - Hepatic metabolism

KW - PDE4

KW - Pharmacokinetics

KW - Phosphodiesterase 4

KW - PK

UR - http://www.scopus.com/inward/record.url?scp=84898634074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898634074&partnerID=8YFLogxK

U2 - 10.1504/IJMEI.2014.060246

DO - 10.1504/IJMEI.2014.060246

M3 - Article

AN - SCOPUS:84898634074

VL - 6

SP - 100

EP - 114

JO - International Journal of Medical Engineering and Informatics

JF - International Journal of Medical Engineering and Informatics

SN - 1755-0653

IS - 2

ER -